MAIA Biotechnology, Inc. (($MAIA)) announced an update on their ongoing clinical study. MAIA Biotechnology, Inc. has announced a new Phase III ...

Vir Biotechnology, Inc. (($VIR)) announced an update on their ongoing clinical study. Vir Biotechnology, Inc. is conducting a Phase 1 study titled ...

Kaigene Inc., a U.S.-based biotechnology company pioneering next-generation antibody therapeutics for autoimmune disorders, announced today that it has entered into an exclusive global licensing ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence ...

Vir's Phase 2 trial saw 39% and 46% HBsAg loss in doublet and triplet regimens for patients with low baseline HBsAg. 100% of participants in the triplet regimen with HBsAg loss achieved anti-HBs ...

A new study published in Nature Biotechnology shows that stem cell differentiation is linked to cellular structures called ...

PDS Biotechnology is hosting a virtual key opinion leader event featuring notable experts in the field, which could enhance the company’s credibility and visibility in the oncological community. The ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a ...

On Tuesday, Sana Biotechnology Inc (NASDAQ:SANA) released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s ...

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks.